Category Press Releases

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB) today announced topline results from the follicular lymphoma (FL) cohort…

Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan SANTA MONICA, Calif.–(BUSINESS WIRE)– Kite Pharma, Inc., a Gilead Company (Nasdaq: GILD), today announced that the Marketing Authorization in Japan for Yescarta® (axicabtagene ciloleucel), a chimeric antigen receptor…

Ad hoc announcement pursuant to Art. 53 LRFerring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors Ferring Pharmaceuticals announced today that Jean-Frédéric Paulsen has been appointed Executive Chairman of the Ferring Group, as it enters a…

People with medical needs are “left behind in pain” reveals new report The World Health Organization (WHO) has published a new report on access to morphine for medical use, which describes how the global distribution of morphine, as a vital pain medicine,…

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced that patients treated with BI 456906 achieved up to 14.9%…

European Commission authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults GSK plc (LSE/NYSE: GSK) today announced that the European Commission has authorised Arexvy (respiratory syncytial virus vaccine, adjuvanted) for active immunisation for the prevention of lower respiratory…

Novo Nordisk A/S and BIOCORP Production SA announced today that Novo Nordisk has entered into exclusive negotiations for a controlling stake in BIOCORP, which would be followed by a mandatory simplified tender offer on all remaining outstanding shares in BIOCORP1 at…

Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA® (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA Moderna, Inc. (Nasdaq: MRNA), a…

GSK receives US FDA file acceptance for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) accepted the supplemental Biologics License…

Datopotamab Deruxtecan Combinations Showed Encouraging TumorResponses in Patients with Advanced Non-Small Cell Lung Cancer inTROPION-Lung02 Phase 1b trial Updated results from the TROPION-Lung02phase 1b trial showed that with additional enrollment and follow-up from the initial presentationdatopotamab deruxtecan (Dato-DXd) in combination…

WHO announces winners of the 4th Health for All Film Festival The World Health Organization has announced the official selection of this year’s winning films at its 4th Annual Health for All Film Festival, held at WHO Headquarters, Geneva. The event,…

Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options  Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE…